+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 0 - 6Hours
All Genders
ID02621944

Melatonin Treatment to Protect Brain in Newborns With Hypoxic Ischemic Encephalopathy Receiving Cooling Therapy

Led by University of Florida · Updated on 2026-06-29

70

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Hypoxic-Ischemic Encephalopathy HIE affects about 20 in 1000 births, and nearly half of the infants treated with the current standard therapy of induced systemic hypothermia do not have normal outcomes. Researchers are exploring additional treatments to improve neurologic results in these infants. This study evaluates the use of melatonin, a naturally produced substance known for regulating sleep cycles and with properties that may protect brain cells by reducing inflammation, oxidative stress, and cell damage in newborns with HIE undergoing hypothermia treatment. Participants will be divided into three groups of ten infants each, receiving increasing doses of melatonin given enterally within 12 hours of birth, targeting 6 hours of life for the first dose. The groups will receive 0.5 mgkg, 3 mgkg, and 5 mgkg doses, respectively, with the higher doses given only if safety is confirmed in the earlier groups. Melatonin will initially be administered as a single dose to some infants to study how hypothermia affects its elimination, followed by multiple doses if no safety concerns arise. Alongside melatonin, participants will undergo Magnetic Resonance Imaging MRI, neurological assessments, pharmacokinetic testing, and safety monitoring. Throughout the study, researchers will monitor melatonin blood levels, side effects, and neurological development up to 18 to 22 months of age using Bayley-III scoring. MRI scans will assess brain impact within 7 to 12 days after birth. The study also measures melatonins effect on inflammation and brain injury markers. Safety data and developmental outcomes will help determine the best tolerated dose and potential benefits of melatonin combined with hypothermia. The trial is expected to complete in March 2027.

CONDITIONS

Brief Title

Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

Research Team

A

Alison A McMurray, M.A.M.C.

K

Kristine Boykin, BSN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here